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Background. Alzheimer’s disease (AD) is the most common cause of dementia in the elderly population. Growing evidence
supports that AD patients are at high risk for hip fracture, but the issue remains questionable. The purpose of the present study
is to perform a meta-analysis to explore the association between AD and risk of hip fracture. Considering that bone mineral
density (BMD) acts as a strong predictor of bone fracture, we also studied the hip BMD in AD patients. Methods. We searched all
publications in Medline, SciVerse Scopus, and Cochrane Library published up to January 2012 about the association between AD
and hip fracture or hip BMD. Results. There are 9 studies included in the meta-analysis. The results indicate that AD patients are at
higher risk for hip fracture (OR and 95% CI ﬁxed: ES = 2.58, 95% CI = [2.03, 3.14]; dichotomous data: summary OR = 1.80, 95%
CI = [1.54, 2.11]) than healthy controls. Further meta-analysis showed that AD patients have a lower hip BMD (summary SMD
= −1.12, 95% CI = [−1.34, −0.90]) than healthy controls. Conclusions. It was found that in comparison with healthy controls AD
patients are at higher risk for hip fracture and have lower hip BMD.
1.Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia among the elderly, and its prevalence is expected to
risesteadilyastheagingpopulation swells[1,2].ADpatients
are at high risk for fractures, particularly of the hip fracture
[3, 4]. Hip fracture is a major cause of disability among older
people and is associated with more deaths and medical costs
relative to all other osteoporosis-related fractures combined
[5]. In recent years, there is a growing evidence supporting
that patients aﬀected by AD have high incidence of hip
fracture[6–8]. We aim to perform a meta-analysis to provide
a comprehensive conclusion on the association between AD
and risk of hip fracture. Since bone mineral density (BMD)
acts as a strong predictor of bone fractures [9], hip BMD
levels in AD patients were also investigated to verify the risk
of hip fracture in AD patients.
2. Methods
2.1. Information Retrieval. With the following terms: “(Alz-
heimer’s disease and hip fracture) or (Alzheimer’s disease
andbonemineraldensity)”,aliteraturesearchwasconducted
in the Medline, Cochrane Library, and SciVerse Scopus
databases up to January 2012. The conference proceedings
and reference lists from retrieved articles were also reviewed
in search of other relevant reports. We used two sets of
parameters to analyze the association between AD and risk
of hip fracture. The ﬁrst set of parameters include the odds
ratio (OR) and 95% conﬁdence intervals (CI) ﬁxed, and
the second set of parameters include the numbers of AD
patients, healthy controls, and fracture patients. As to BMD,
we needed the numbers of AD patients and healthy controls,
the BMD mean, and standard deviation values for both pa-
tient and healthy control groups. BMD (mm Al) was meas-
ured at the right second metacarpal using a computer-linked
X-ray densitometer (CXD) (Teijin, Tokyo, Japan) [10]. In
total, 9 studies were ﬁnally included in the present meta-
analysis (Figure 1), among which, 3 studies (OR and 95%
CI ﬁxed) [11–13] and 4 studies (dichotomous data) [11,
12, 14, 15] reported risk of hip fracture in AD patients,
and 4 studies [16–19] studied the hip BMD in AD pa-
tients.2 The Scientiﬁc World Journal
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Figure 1: Selection of studies for inclusion in the meta-analysis.
2.2. Statistical Analysis. All analyses were performed using
the Stata 12.0 statistical software. We used the parameters
from each study about 95% CI, OR, the standardized mean
diﬀerence (SMD), and the eﬀect size (ES). The heterogeneity
was evaluated via the I-square test and Chi-square. If the
P value was greater than 0.10 and the I2 value was less
than 50%, the study was considered not to report signiﬁcant
diﬀerences.
3. Results
3.1. Association between AD and Risk of Hip Fracture. There
are 3 studies showing OR and 95% CI ﬁxed and 4 studies
showing dichotomous data which met the eligibility criteria.
Table 1 shows the ﬁrst author, year of publication, OR, 95%
CI, patient weight, ES, and 95% CI of each study. Table 2
shows the ﬁrst author, year of publication, number of AD
cases and controls, number of hip fracture patients, patient
weight, OR, and 95% CI of each study. The country, percent-
age of women patients, and average patient age of each study
were also shown in Table 3. The results of the meta-analysis
areshowninFigures2and3,whichindicatethatADpatients
are athigher risk forhip fracture(ORand 95% CI ﬁxed: ES =
2.58, 95% CI = [2.03, 3.14]; dichotomous data: summaryOR
= 1.80, 95% CI = [1.54, 2.11]) and heterogeneity is not found
among these studies (OR and 95% CI ﬁxed: P = 0.588, I2 =
0.0%; dichotomous data: P = 0.428, I2 = 0.0%).
3.2. Association between AD and Hip BMD. There are 4 stud-
ies (including 551 AD patients and 540 controls) reporting
the hip BMD level in AD which met the eligibility criteria.
Summary of these studies is given in Table 4. The meta-
analysis results in Figure 4 indicate that AD patients have
a lower hip BMD than healthy controls (summary SMD =
−1.12, 95% CI = [−1.34, −0.90]).
4. Discussion
As a progressive neurodegenerative disease, the symptoms
of AD include progressive loss of memory and cognitive
function and apraxia [20]. Hip fracture is associated with
considerable disability and loss of independence [21–23].
Recent accumulating studies indicated that both hip fracture
and AD patients exhibit many similar conditions such as
lower weight, lower vitamin D levels, lower gastrointestinal
absorption of calcium, and higher parathyroid hormone
(PTH) levels [24–28]. Some studies proposed that AD
patients are at high risk for hip fracture [6–8]. This meta-
analysis aims to provide a comprehensive evaluation on the
association between AD and risk of hip fracture based on the
available published references. The results (OR and 95% CI
ﬁxed: ES = 2.58, 95% CI = [2.03, 3.14]; dichotomous data:
summary OR = 1.80, 95% CI = [1.54, 2.11]) suggest that AD
patients are at higher risk for hip fracture. Moreover, it was
found that AD patients have a lower hip BMD, a predictor
of fracture, than healthy controls (summary SMD = −1.12,
95% CI = [−1.34, −0.90]).
Multiple factors may help to understand the association
between AD and risk of hip fracture. It has been widely
reported that in comparison with healthy controls AD
patients have lower levels of 25(OH)D and calcium [29,
30]. Vitamin D status is an important factor of skeletal
integrity, and inadequate serum 25(OH)D level is associated
with muscle weakness and increased incidences of falls and
fractures [31]. Lower levels of vitamin D and calcium can
also induce compensatory hyperparathyroidism, which may
further contribute to a reduction in BMD [32]. Thus, it
can be inferred that vitamin D and calcium deﬁciency may
be an important factor. In addition, parathyroid hormone
(PTH) may act as another important factor. Elevated PTH
concentrations are associated with cognitive decline and may
increase tissue aluminum loads which is a factor in the
pathogenesis of AD [33, 34]. Meanwhile, it has been found
that the high intact bone Gla protein and pyridinoline cross-
linked carboxyterminal telopeptide of type I collagen with
PTH induce compensatory hyperparathyroidism to increase
bone turnover to raise the risk of fracture [17].
The present meta-analysis has some limitations. First,
many factors including anti-AD drugs, exposure to sunlight,
and food intake which may inﬂuence the AD progression
are not considered in the meta-analysis. Second, the number
of studies included in the present study is relatively small.
Third, we did not consider AD severity, which can vary the
prevalence of hip fracture.
5. Conclusions
To summarize, the meta-analysis indicates that AD patients
areathighriskforhipfractureandhavelowerhipBMDthanThe Scientiﬁc World Journal 3
Table 1: Summary of the studies of the association between AD and hip fracture (OR and 95% CI ﬁxed).
References OR 95% CI Weight (%) ES 95% CI
[11] 2.80 [2.30, 3.70] 62.07 2.80 [2.30, 3.70]
[12] 2.40 [1.41, 4.10] 16.81 2.40 [1.41, 4.10]
[13] 2.10 [1.20, 3.60] 21.12 2.10 [1.20, 3.60]
Table 2: Summary of the studies of the association between AD and hip fracture (dichotomous data).
References NN Weight(%) OR 95% CI
Fracture AD Fracture Control
[11] 391 10052 226 10052 90.75 1.73 [1.47, 2.04]
[12] 31 528 25 985 6.96 2.31 [1.35, 3.96]
[14] 10 20 12 60 1.95 2.50 [0.94, 6.66]
[15] 5 44 1 56 0.34 6.36 [0.72, 56.47]
Table 3: Country, gender, and mean age of the references included in the meta-analysis of AD and hip fracture.
References Country
Gender (% female) Mean age (year)
AD Control AD Control
[11] UK 65.5 — 79 ±7.9—
[12]C a n a d a 3 7 — ≥65 ≥65
[13]C a n a d a — — ≥65 ≥65
[14] America 100 100 60 60
[15] America 52.3 51.8 71.5 ±5.37 1 .4 ±4.5
Table 4: Summary of the studies of the association between AD and hip BMD.
References
N BMD (mmAl)
Weight(%) SMD 95% CI
AD Control AD Control
[16] 46 140 1.738 ±0.303 2.047 ±0.167 19.36 −1.48 [−1.85, −1.12]
[17] 205 200 2.124 ±0.405 2.550 ±0.360 30.12 −1.11 [−1.32, −0.90]
[18] 100 100 1.669 ±0.324 2.000 ±0.250 23.49 −1.14 [−1.44, −0.84]
[19] 200 100 1.885 ±0.305 2.130 ±0.240 27.03 −0.86 [−1.11, −0.61]
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Figure 2: Pooled estimate of ES and 95% CI of AD and hip fracture (used OR and 95% CI ﬁxed). ES is represented by squares, whose sizes
are proportional to the sample size of the relative study. The whiskers represent the 95% CI. The diamond represents the pooled estimate
based on the random eﬀects model, with the centre representing the point estimate and the width the associated 95% CI.4 The Scientiﬁc World Journal
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Figure 3: Pooled estimate of OR and 95% CI of AD and hip fracture (used dichotomous data). OR is represented by squares, whose sizes are
proportional to the sample size of the relative study. The whiskers represent the 95% CI. The diamond represents the pooled estimate based
on the random eﬀects model, with the centre representing the point estimate and the width the associated 95% CI.
Note: Weights are from random effects analysis
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Figure 4: Pooled estimate of SMD and 95% CI of AD and hip BMD (mmAl). SMD is represented by squares, whose sizes are proportional to
the sample size of the relative study. The whiskers represent the 95% CI. The diamond represents the pooled estimate based on the random
eﬀects model, with the centre representing the point estimate and the width the associated 95% CI.
healthy controls. More eﬀorts are warranted to elucidate the
mechanisms underlying these associations.
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